Cadralazine Versus Prazosin As Second-step Treatment in Hypertensive Patients on Beta-blockers: a Randomized Multicentre Study. The Italian Multicentre Study Group

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1991 Jan 1

PMID 1679390

Citations 1

Authors

S Caponnetto

E Valvo

P Mocarelli

D Alberti

S Savonitto

Affiliations

Soon will be listed here.

Abstract

A randomized multicentre between-patient study comparison has been made of the efficacy and tolerability of cadralazine and prazosin, both administered for 6 weeks to hypertensive patients with a supine diastolic blood pressure (DBP) greater than or equal to 95 mmHg whilst on a beta-adrenoceptor-blocker. The doses of the beta-adrenoceptor-blocker (metoprolol SR 200 mg once daily) and cadralazine (10 mg once daily) were held constant during the study, while prazosin was individually titrated from 0.5 mg to a maximum of 2 mg tds. 108 patients (50 m and 58 f; mean age 54 y) were enrolled in 12 centres. Twelve patients withdrew due to adverse effects or poor efficacy (5 patients on prazosin and 7 on cadralazine). Both treatments induced a similar significant reduction in systolic blood pressure (SBP) and DBP, allowing normalization of BP in 58% of subjects on cadralazine and 55% on prazosin. Heart Rate (hR) increased significantly from 67 to 72 beats.min-1 in those on cadralazine and from 65 to 69 beats.min-1 on prazosin. Body weight was unchanged. Adverse effects were mild and typical of vasodilators, such as headache, flushing and dizziness. Physician evaluation of drug efficacy was not different between drugs, and cadralazine was rated better in terms of tolerability. Thus, in this multicentre study, cadralazine in the fixed dose of 10 mg once daily, as a second-step antihypertensive treatment in patients not satisfactorily controlled by a beta-adrenoceptor-blocker, was as effective and showed a similar side effect profile to prazosin given three times daily.

Citing Articles

Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

McTavish D, Young R, Clissold S Drugs. 1990; 40(4):543-60.

PMID: 2083513 DOI: 10.2165/00003495-199040040-00005.

References

van Brummelen P, Buhler F, Kiowski W, Bolli P, Bertel O . Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic. Int J Clin Pharmacol Biopharm. 1979; 17(10):380-5. View

DUSTAN H, Taylor R, CORCORAN A . Rheumatic and febrile syndrome during prolonged hydralazine treatment. J Am Med Assoc. 1954; 154(1):23-9. DOI: 10.1001/jama.1954.02940350025006. View

Eggertsen R, Hansson L . Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers. Int J Clin Pharmacol Ther Toxicol. 1985; 23(8):411-23. View

Colucci W . Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. Ann Intern Med. 1982; 97(1):67-77. DOI: 10.7326/0003-4819-97-1-67. View

Salvadeo A, Villa G, Segagni S, Piazza V, Picardi L, Romano M . Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. Arzneimittelforschung. 1985; 35(3):623-5. View

Semeraro C, DORIGOTTI L, Banfi S, CARPI C . Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. J Cardiovasc Pharmacol. 1981; 3(3):455-67. DOI: 10.1097/00005344-198105000-00005. View

Marshall A, McGraw M, Barritt D . Positive antinuclear factor tests with prazosin. Br Med J. 1979; 1(6157):165-6. PMC: 1597589. DOI: 10.1136/bmj.1.6157.165. View

Persson B, Granerus G, Wysocki M, Hedner T, Andersson O . Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. Eur J Clin Pharmacol. 1987; 31(5):513-8. DOI: 10.1007/BF00606622. View

Andersson O . Cadralazine did not produce the SLE-syndrome when hydralazine did. Eur J Clin Pharmacol. 1987; 31(6):741. DOI: 10.1007/BF00541309. View

10.

Okun R . Effectiveness of prazosin as initial antihypertensive therapy. Am J Cardiol. 1983; 51(4):644-50. DOI: 10.1016/s0002-9149(83)80202-1. View

11.

Stanaszek W, Kellerman D, Brogden R, Romankiewicz J . Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 1983; 25(4):339-84. DOI: 10.2165/00003495-198325040-00002. View

12.

Gottlieb T, KATZ F, CHIDSEY 3rd C . Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972; 45(3):571-82. DOI: 10.1161/01.cir.45.3.571. View

13.

Hansson L, Olander R, Aberg H, MALMCRONA R, Westerlund A . Treatment of hypertension with propranolol and hydralazine. Acta Med Scand. 1971; 190(6):531-4. DOI: 10.1111/j.0954-6820.1971.tb07470.x. View

14.

KATILA M, FRICK M . Combined dihydralazine and propranolol in the treatment of hypertension. Int Z Klin Pharmakol Ther Toxikol. 1970; 4(1):111-4. View

15.

Catalano M, Parini J, Romano M, LIBRETTI A . Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension. Eur J Clin Pharmacol. 1985; 28(2):135-8. DOI: 10.1007/BF00609680. View

16.

Bouthier J, Safar M, Curien N, London G, Levenson J, Simon A . Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. Clin Pharmacol Ther. 1986; 39(1):82-8. DOI: 10.1038/clpt.1986.14. View

17.

Koshy M, Mickley D, Bourgiognie J, BLAUFOX M . Physiologic evaluation of a new antihypertensive agent: prazosin HCl. Circulation. 1977; 55(3):533-7. DOI: 10.1161/01.cir.55.3.533. View

18.

Catalano M, Parini J, LIBRETTI A . Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients. Eur J Clin Pharmacol. 1983; 24(2):157-61. DOI: 10.1007/BF00613810. View

19.

Strocchi E, Costa F, Caldari R, Malini P, Marata A, Parini J . Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment. Int J Clin Pharmacol Ther Toxicol. 1983; 21(10):519-23. View

20.

BUONINCONTI R, Motolese M . Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker. Int J Clin Pharmacol Ther Toxicol. 1985; 23(11):613-6. View